Stock 002252 SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Funds and ETFs Shanghai RAAS Blood Products Co., Ltd.

Equities

002252

CNE100000C31

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 30/06/2024 BST 		5-day change 1st Jan Change
7.96 CNY +1.79% Intraday chart for Shanghai RAAS Blood Products Co., Ltd. +2.98% -0.50%
06-20 Haier Gets Regulatory Nod to Buy Controlling Stake in RAAS Blood Products MT
06-19 RAAS Blood Products Renews Cooperation Deal With Spain's Grifols MT

ETFs positioned on Shanghai RAAS Blood Products Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
0.71% 2 M€ -14.14%
KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX UCITS ETF - USD ETF KraneShares MSCI All China Health Care Index UCITS ETF - USD
0.69% 1 M€ -23.18% -
ICBCCS S&P CHINA 500 UCITS ETF CLASS B - USD ETF ICBCCS S&P China 500 UCITS ETF Class B - USD
0.05% 35 M€ -5.85% -
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY UCITS ETF - ACC - USD ETF Goldman Sachs ActiveBeta Emerging Markets Equity UCITS ETF - Acc - USD
0.04% 11 M€ +6.19%
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.01% 4 M€ -4.41% -
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 114 M€ +5.53% -
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR
0.00% 451 M€ +8.73% -
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR
0.00% 2,838 M€ +11.22% -
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD
0.00% 152 M€ +7.69% -
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD ETF Day Hagan/Ned Davis Research Smart Sector International ETF - USD
0.00% 35 M€ +5.52% -
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF Acc - EUR
0.00% 414 M€ +11.15% -
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF - Distributing - EUR
0.00% 36 M€ +9.99% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 32 M€ +4.15% -
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Distributing - EUR
0.00% 40 M€ +6.78% -
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Acc - EUR
0.00% 324 M€ +7.72% -
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF - Distributing - EUR
0.00% 17 M€ +2.74% -
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF Acc - EUR
0.00% 104 M€ +4.56% -
DEMOCRACY INTERNATIONAL FUND ETF - USD ETF Democracy International Fund ETF - USD
0.00% 7 M€ +4.16% -
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF Acc - EUR
0.00% 55 M€ +1.10% -
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY ETF Nomura NEXT FUNDS Emerging Market Equity MSCI-EM (Unhedged) ETF - JPY
0.00% 15 M€ +22.37%
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF - Distributing - EUR
0.00% 8 M€ -0.41% -

Company Profile

Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin). China accounts for 96.6% of net sales.
Sector
Pharmaceuticals
Calendar
27/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai RAAS Blood Products Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
7.82 CNY
Average target price
6.55 CNY
Spread / Average Target
-16.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. Stock Shanghai RAAS Blood Products Co., Ltd.
-0.50% 7.11B
CSL LIMITED Stock CSL Limited
+2.08% 95.18B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-0.13% 37.55B
BIOGEN INC. Stock Biogen Inc.
-10.25% 33.75B
UCB Stock UCB
+77.76% 28.2B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.33% 15.63B
INCYTE CORPORATION Stock Incyte Corporation
-2.79% 13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.76% 11.5B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+181.73% 10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-53.92% 9.23B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 002252 Stock
  4. Funds and ETFs Shanghai RAAS Blood Products Co., Ltd.